Hualan Biological Engineering (SHE:002007) subsidiary Hualan Biological Vaccine received clinical trial approval from China's National Medical Products Administration for its novel influenza virus mRNA vaccine.
The drug is used to prevent influenza with vaccine-matched flu virus strains, according to a Tuesday filing with the Shenzhen bourse.
The drug company's shares fell 2% during afternoon trading on Tuesday.